$ICLR

Grais Linda sold $138K of ICLR

Grais Linda sold 841 shares of ICON PLC (ICLR) at an average of $164.29 ($162.72–$165.51, $0.14M total) across 4 trades on 2026-08-11.

Original reporting
SEC EDGAR · Grais Linda
Published Aug 12, 2026, 8:47 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 9:07 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ICLR
Neutral
medium confidence
Mentioned
$ICLR
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ICLRNeutralLow
01

Why it matters

The newest fact is the disclosed sale size, price range ($162.7200 to $165.5100), and post-transaction holdings (6,162 shares). This can influence short-term sentiment but does not change company fundamentals in the text.

02

Market read

Traders may monitor ICLR for any follow-on insider activity, but the filing alone is unlikely to drive a durable repricing without accompanying fundamental news.

03

What to watch

The article provides only the sale details; it does not state the director’s broader trading history, tax planning context, or whether other insiders simultaneously bought/sold.

Relevance 4/10Novelty 5/10Timing: filed 2026-08-12 after-hours; reflects 2026-08-11 insider sale

Background

The article is an SEC Form 4 insider transaction disclosure for ICON PLC (ICLR) by director Grais Linda.

Company-level read

Ticker impact

$ICLRNeutralMedium confidence
Context

ICON PLC director Grais Linda sold 841 shares in an open-market transaction totaling $138,168.80, per a newly filed Form 4.

Expected impact

Low likelihood of sustained price impact; any reaction is likely limited to short-term sentiment around insider selling.

Evidence & confidence

The filing is a primary-source Form 4 disclosure, but it does not include new company fundamentals, guidance, or deal terms. The sale is also described as not under a pre-arranged 10b5-1 plan, which can increase attention but still lacks a direct causal link to operations.

Market effects

No clear sector read-through from a single director open-market sale.

None indicated.

None indicated.

Counterpoint

The absence of a 10b5-1 plan could be interpreted as more discretionary selling, but insider sales are often driven by personal liquidity needs rather than bearish fundamentals.

Key entities

  • ICON PLC

    Subject of the Form 4 insider transaction disclosure.

  • Grais Linda

    Director who sold 841 shares across four trades on 2026-08-11.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ICLRMedAI 9/10

ICON plc: ICON Reports Second Quarter 2026 Results

ICON plc (NASDAQ: ICLR) reported Q2 2026 results. Revenue was $2,063.5 million, up 1.4% QoQ. Adjusted EBITDA was $327.2 million (15.9% of revenue). GAAP net income was $72.6 million ($0.94 diluted EPS) and adjusted net income was $198.4 million ($2.56 adjusted EPS). Net business wins were $3,120 million, backlog $23.4 billion, and it reaffirmed 2026 guidance.

$ICLRHighAI 8/10

ICON PLC (ICLR): Financial results for Q2 2026

ICON PLC (ICLR) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 ICON Reports Second Quarter 2026 Results Highlights • Quarter two revenue of $2,063.5 million, an increase of 1.4% on quarter one 2026. • Quarter two adjusted EBITDA of $327.2 million or 15.9% of revenue, an increase of 3.0% on quarter one 2026. • GAAP net income for

$ICLRMed

ICON stock surges 7% on Anthropic AI partnership for trials By Investing.com

ICON plc (NASDAQ:ICLR) shares rose about 7.8% after the company announced a multi-year partnership with Anthropic to integrate Claude AI into its Orbis clinical trial platform. ICON said the collaboration will add four production capabilities, including site intelligence and enrollment risk detection, and will roll out Claude across roles. ICON cited enrollment delays affecting up to 80% of trials.

$ICLRMed

ICON, Anthropic Sign Multi-Year Partnership Deal To Advance AI Capabilities, Stock Up In Pre-Market

ICON Public Limited Company (ICLR) said it signed a multi-year partnership with Anthropic to integrate Claude AI across the clinical trial lifecycle using ICON’s Orbis platform. ICON plans to work with Anthropic’s life sciences team and deploy Claude Code, Claude, and Claude Science. The company cited CEO Barry Balfe. In pre-market, ICLR rose to $177.69, up 5.28% on Nasdaq.